Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $193M
Founded date: 2021
Investors 3
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | F-Prime Ca... | fprimecapi... |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.02.2023 | Series B | $193M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.02.2023 | Aera Therapeutics Launches with $193M in Series A and Series B Financing | Aera Therapeutics, a Boston, MA-based biotechnology company providing a proprietary protein nanoparticle (PNP) delivery platform, raised $193M in combined Series A and B financings. The rounds was led by ARCH Venture Partners, GV and Lux Ca... |
| 16.02.2023 | On hunt for better gene med delivery, Aera exits stealth with $193M and Alnylam vet at helm | Led by a 20-year Alnylam veteran, Aera Therapeutics has emerged with $193 million in hand and hopes of unlocking genetic medicine’s fullest potential. “There's still a lot of money out there,” Aera CEO Akin Akinc, Ph.D., told Fierce Biotech... |
| - | Aera Therapeutics | “Aera Therapeutics” |